Nejat K. Egilmez, Ph. D.
CO-FOUNDER & EXECUTIVE VICE PRESIDENT
Dr. Egilmez is the co-founder of TheraPYX Inc. and serves as the company’s Executive Vice President. Dr. Egilmez received his Ph.D. degree from the Department of Cell and Molecular Biology of The State University of New York at Buffalo. He is currently Professor and Chair of the Department of Microbiology and Immunology in the School of Medicine at University of Louisville. Dr. Egilmez’s academic research interests include immune regulation and therapy in cancer and inflammatory diseases. His laboratory pioneered the use of sustained-release nano/microparticulate protein formulations for cancer and inflammatory/infectious disease therapy. Dr. Egilmez directs the company’s research and business efforts.
Dominick L. Auci, MBA, Ph.D.
VICE PRESIDENT FOR RESEARCH AND DEVELOPMENT
Dr. Auci brings over twenty years of pharmaceutical experience, including a decade as Assistant Professor of Pathology at SUNY Health Science Center at Brooklyn and another ten years as Director of Autoimmunity and Inflammation at Hollis-Eden Pharmaceuticals in San Diego, California. His responsibilities included management of drug development from inception through phase I/II testing. Dr. Auci received his Ph.D. in cellular immunology from Downstate Medical Center and also earned an MBA in Executive Management from Baruch College. He has contributed to and coordinated several IND application and has authored over 40 peer-reviewed publications.
Michael W. Russell, Ph.D.
CHIEF SCIENTIFIC OFFICER
Dr. Russell is an internationally-recognized expert and leader in mucosal immunity to infections of the mouth and genital tract. He joined TheraPYX, Inc. as CSO in 2018. He is also Emeritus Professor of Microbiology & Immunology at SUNY/Buffalo. His laboratory developed novel approaches for inducing protective immunity to genital tract infections, especially by Neisseria gonorrhoeae, based on understanding of the manner in which these organisms exploit and manipulate the host’s immune system. Dr. Russell oversees the scientific programs of the Company with specific focus on infectious disease therapeutics including GneX12TM and NGoXIM™.
Aral A. Egilmez, Esq.
Mr. Egilmez is a 2016 graduate from the State University of New York at Buffalo Law School, and is fully admitted to practice in the State of New York. Mr. Egilmez also earned two Bachelor’s Degrees from Niagara University. His Bachelors’ consist of one in Liberal Arts with a focus in American Legal History, and one in Political Science. Before beginning his career in Corporate Law, Mr. Egilmez briefly worked as an Immigration Attorney where he handled the Business Law aspects of various cases. Later, and during his experience in the field of Immigration – Mr. Egilmez performed critical Pro Bono services for indigent refugees at the Survivors of Torture Recovery Center in Louisville, Kentucky. After shifting interests towards an in-house career, Mr. Egilmez began work as a Contract Attorney where after performing various services for TheraPYX, Inc. he was hired as an Associate Counsel. Most recently, Mr. Egilmez has taken on the role of General Counsel for TheraPYX, Inc. where he manages everything from Intellectual Property protection and Contracts, to Alternative Dispute Resolution and settlements.